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The expression of many antigens, stimulatory molecules, or evenmetabolic pathways in mycobacteria such asMycobacterium
bovis BCG orM. smegmatiswas made possible through the development of shuttle vectors, and several recombinant vaccines
have been constructed. However, gene expression in any of these systems relied mostly on the selection of natural promoters
expected to provide the required level of expression by trial and error. To establish a systematic selection of promoters with a
range of strengths, we generated a library of mutagenized promoters through error-prone PCR of the strong PL5 promoter, origi-
nally frommycobacteriophage L5. These promoters were cloned upstream of the enhanced green fluorescent protein reporter
gene, and recombinantM. smegmatis bacteria exhibiting a wide range of fluorescence levels were identified. A set of promoters
was selected and identified as having high (pJK-F8), intermediate (pJK-B7, pJK-E6, pJK-D6), or low (pJK-C1) promoter strengths
in bothM. smegmatis andM. bovis BCG. The sequencing of the promoter region demonstrated that it was extensively modified
(6 to 11%) in all of the plasmids selected. To test the functionality of the system, two different expression vectors were demon-
strated to allow corresponding expression levels of the Schistosoma mansoni antigen Sm29 in BCG. The approach used here can
be used to adjust expression levels for synthetic and/or systems biology studies or for vaccine development to maximize the im-
mune response.
Mycobacterium bovis BCG is currently the world’s most widelyused vaccine and has been given to more than three billion
people, making it a very attractive prospect for the development of
a live recombinant BCG (rBCG) multivaccine (1). The first gen-
eration of rBCG vaccines was developed in the 1990s as rBCG
strains that expressed homologous and heterologous antigens
from a wide range of pathogens (2–5). Stability of the heterolo-
gous (or native) gene(s) in BCG was usually obtained by cloning it
on a plasmid or chromosomally integrative vector with expression
achieved by placing it under the control of a range of mycobacte-
rial promoters (2). The heat shock protein promoters (PHsp60
from BCG and PHsp70 from M. tuberculosis), the IS900 open read-
ing frame promoter (PAN from M. paratuberculosis), and the mu-
tated -lactamase promoter (PBlaF* from M. fortuitum) are the
ones used most, as reviewed in reference 2. However, the lack of
knowledge of the transcriptional mechanisms regulating myco-
bacterial promoters results in unpredictable gene expression lev-
els. Yet the level of antigen expression is likely to be a crucial factor
in both the strength and the pattern of subsequent immune re-
sponses. For example, a study in which expression of M. tubercu-
losis antigen 85B (Ag85B) in rBCG was placed under the control of
a limited set of promoters found that increasing promoter activity
caused a skewing of the immune response to Ag85B in mice from
a mixed Th1/Th2 response to a predominantly Th1 response (6).
In another study, increasing expression of M. tuberculosis 19-kDa
lipoprotein led to complete abrogation of the protective efficacy of
BCG by polarizing the host immune responses to the Th2 subtype
(7). Another important factor for any vaccine vector is stability
and the associated metabolic burden, which can lead to loss of
antigen expression and/or premature elimination of the vector in
the host because of loss of fitness (8). Indeed, loss of vector during
replication in the host is thought to have been responsible for the
failure of an rBCG vaccine expressing outer surface protein A
(OspA) ofBorrelia burgdorferi to generate an appropriate immune
response in a clinical trial, despite the apparent efficacy of the
vaccine in mice (9). Our own earlier studies similarly demon-
strated vector instability and a lack of correlation of immune re-
sponses in mice with expression levels in vitro (10).
To improve the genetic control of gene expression in mycobac-
teria, different tools and strategies can be used, such as inducible
promoters (11), synthetic genes with codon-optimized sequences
(12, 13), substitution of the initiation codon (14), addition of
Shine-Dalgarno sequences (15), an increase in the plasmid copy
number (16), or integration into the mycobacterial genome (17).
However, once again, expression levels are often unpredictable
and may be further complicated by regulatory influences on ex-
pression levels, particularly during growth in the host environ-
ment. In this work, as a first step toward a more rational approach
to vaccine vector design, we engineered the mycobacteriophage
promoter PL5 (18). Our aim was to generate a set of mycobacterial
promoters that can be used to obtain a predictable range of gene
expression levels in both M. smegmatis and M. bovis BCG.
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MATERIALS AND METHODS
Ethics statement. This study was conducted in accordance with the rec-
ommendations and with the approval of the Committee on the Ethics of
Animal Experiments of the Butantan Institute under protocol 594/09.
Bacterial strains and plasmids. Escherichia coli DH5 (19) (Invitro-
gen) was used in all cloning steps with lysogeny broth (LB) or LB plates
with kanamycin (20 g/ml) for selection of transformants. M. smegmatis
strain MC2155 (20) and M. bovis BCG strain Pasteur (21) were grown at
37°C in Difco Middlebrook 7H9 broth (Becton, Dickinson) enriched with
10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC), 0.5% glyc-
erol, and 0.05% Tween 80 (MB7H9) containing kanamycin when neces-
sary. Electrocompetent M. smegmatis and BCG were transformed by elec-
troporation as previously described (22), and transformants were selected
on Middlebrook 7H10 agar plates with OADC (MB7H10) and kanamy-
cin. All primers were purchased from Eurofins MWG Operon (Ebersberg,
Germany), and all restriction enzymes were from New England BioLabs
(Hitchin, United Kingdom). GoTaq DNA polymerase (Promega, South-
ampton, United Kingdom) was used in all PCRs. The expression cassette
of the pBRL8 plasmid (kindly provided by William Jacobs, Jr., Yeshiva
University, New York, NY) containing the PL5 promoter and the egfp gene
was PCR amplified with primers 5=-TAGGGTACCTCTAGAGGAAACA
GCTATGACCAT-3= (the KpnI and XbaI restriction sites are underlined
and in bold, respectively) and 5=-TAGATCGATCAGCTGTTACTTGTA
CAGCTCGT-3= (the ClaI and PvuII restriction sites are underlined and in
bold, respectively). This fragment was cloned into pJH152 (kindly pro-
vided by Stewart T. Cole, Ecolé Polytechnique Fédérale de Lausanne, Lau-
sanne, Switzerland) between the KpnI and PvuII restriction sites, thus
generating pJH-egfp (Fig. 1A). Next, error-prone PCR of the promoter
sequence was carried out in the presence of 25M 8-oxo-dGTP and 5M
dPTP (Jena Bioscience, Germany), along with 400 M natural deoxy-
nucleoside triphosphates (dNTPs) (Fig. 1B). According to the manufac-
turer’s instructions, 20 rounds of amplification were performed with
primers 5=-TAGGTTTAAACAAACGGAAACAGCTATGACCAT-3= (the
PmeI restriction site is in bold) and 5=-TAGCATATGCGATCTCCCTTT
CCCGT-3= (the NdeI restriction site is in bold). Plasmid pJH-egfp and the
PCR product were digested with PmeI and NdeI, resolved in an agarose
gel electrophoresis to remove the original cassette and clean up the PCR
product, and further purified with the QIAquick PCR Purification kit
(Qiagen, Hilden, Germany). Before ligation, the digested vector was
treated with calf intestinal alkaline phosphatase (Promega) in accordance
with the manufacturer’s instructions for the dephosphorylation of 5=
overhangs and purified once again. Digested fragments were allowed to
ligate with T4 DNA ligase (Promega) at 16°C for 16 h and used to trans-
formE. coliDH5. Plasmid DNA was extracted from approximately 2,000
colonies in a pool, generating a pJK plasmid library that, in turn, was used
in the electroporation of M. smegmatis MC2155 with a Bio-Rad Gene
Pulser II apparatus (Bio-Rad, Hercules, CA). Transformants were allowed
to grow for 3 to 5 days on MB7H10-kanamycin plates (Fig. 1B). Plasmid
pJH137 was digested with restriction enzymes XbaI and NdeI to remove
the heat shock promoter PHsp60 and insert it in place of PL5 of pJH-egfp,
generating pJHsp60. Plasmid pET-21 containing the Sm29 sequence to
produce rSm29 protein was previously constructed (23).
Screening of fluorescent M. smegmatis. After visualization of M.
smegmatis transformants by eye, approximately 200 colonies were isolated
FIG 1 Schematic representation of pJH-egfp and the methodology used to
generate a functional promoter library. (A) pJH-egfp contains the PL5 pro-
moter upstream of the egfp sequence, a kanamycin resistance marker
[Kan(R)], and origins of replication in E. coli (oriC) and mycobacteria (oriM).
(B) The PL5 promoter was submitted to error-prone PCR and used to drive the
expression of egfp. M. smegmatis transformants were selected by kanamycin
resistance, and functional promoters were screened within fluorescent colo-
nies. Selected colonies spanning a wide range of fluorescence levels were fur-
ther analyzed by microscopy, specific promoter mutations, and single-cell flu-
orescence by flow cytometry. (Adapted from reference 26.)
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and grown in MB7H9-kanamycin. Samples were allowed to grow for 16 h
and screened on 96-well black plates in duplicate with a PerkinElmer
Victor 3 fluorescence multiplate reader (PerkinElmer, Waltham, MA) set
up for excitation and emission wavelengths of 485 and 535 nm, respec-
tively. Also, the optical density at 620 nm (OD620) of each sample was
measured. The fluorescence of the strains was initially screened in fluo-
rescence units (FU), and then, following normalization by OD, five strains
were selected on the basis of measurements of relative FU (RFU). The
plasmid in each of these transformants was extracted with the illustra
plasmidPrep Mini Spin kit (GE Healthcare Life Sciences, Freiburg, Ger-
many), and PL5 promoters were sequenced with the primer 5=-TCAGCT
TGCCGTAGGTGGCA-3=.
Characterization of GFP expression and in vitro growth of selected
mutants. Shaking flasks with MB7H9-kanamycin were inoculated with
selected M. smegmatis/pJK in triplicate to an OD of0.1. Culture turbid-
ity and fluorescence were monitored every hour. For comparison, wild-
type M. smegmatis strain MC2155 grown in MB7H9 was also analyzed. A
FACSCanto II flow cytometer (Becton, Dickinson) was used to determine
the single-cell fluorescence of gated bacterial cells on the basis of the me-
dian of fluorescein isothiocyanate (FITC; with 488-nm excitation and
500- to 560-nm emission filters). Turbidity was measured with an Ultro-
spec 2000 spectrophotometer (Pharmacia Biotech, Sweden). To compare
the newly generated promoters with a widely used one, PHsp60 was in-
serted in place of PL5. M. bovis BCG bacteria containing these plasmids
were analyzed and compared with M. smegmatis constructs. Late-log-
phase cultures of recombinant M. smegmatis strains were disrupted on ice
with a GE 100 Ultrasonic Processor at half-maximum constant output,
and the protein concentration in culture lysates was determined by the DC
Protein Assay (Bio-Rad) with bovine serum albumin as the standard.
Approximately 10 g of soluble protein extracts was separated by SDS-
PAGE and stained with Coomassie brilliant blue (Bio-Rad). The predicted
molecular mass of GFP is 28.3 kDa (http://web.expasy.org/compute_pi/).
Following destaining, the band corresponding to GFP’s molecular weight
was analyzed by densitometry with ImageJ software.
Microscopy analysis of selected strains. M. smegmatis/pJK strains
were observed under a microscope. Late-log-phase cultures were washed
twice with phosphate-buffered saline and placed on microscope slides.
Images were acquired on an LSM 510 META confocal system (Zeiss, Ger-
many) with a 488-nm laser for excitation and a 500- to 550-nm bandpass
filter for emission.
Fine-tuned expression of foreign antigen. To assess the usefulness of
the pJK library regardless of the downstream gene under its regulation, we
used three plasmids containing the mutagenized promoters, pJK-F8, pJK-
B7, and pJK-C1. For this model, we removed the egfp gene by digestion
with NdeI and PvuII and cloned the partial sequence of the Schistosoma
mansoni gene sm29 (GenBank accession no. AF029222) codon optimized
for expression in mycobacteria, as this antigen is currently considered a
vaccine candidate (23), creating pJK-F8.sm29, pJK-B7.sm29, and pJK-
C1.sm29. Codon optimization was performed by the DNA 2.0 company
according to their patented algorithm. Codon-optimized sm29 had an
increased GC content (from 37 to 51%). BCG was transformed with these
constructs and allowed to grow as described previously. Kanamycin-re-
sistant clones were grown until late log phase, disrupted on ice, and quan-
tified as previously described. Approximately 25 g of total protein ex-
tracts was separated by SDS-PAGE, and proteins were electrotransferred
to a polyvinylidene difluoride membrane (GE Healthcare) and blocked
for 16 h at 4°C in a 5% nonfat dry milk solution. Western blotting of Sm29
expression used polyclonal mouse anti-rSm29 antibody (1:1,000) and a
horseradish peroxidase (HRP)-conjugated anti-mouse antibody ad-
sorbed to human serum proteins (KPL, Gaithersburg, MD) at 1:3,000.
The chemiluminescent signal was detected with the Immobilon Western
Chemiluminescent HRP Substrate (Merck, Darmstadt, Germany), and
images were acquired with the LAS4000 digital imaging system (GE).
Recombinant Sm29 protein and anti-rSm29 antibody production.
Recombinant Sm29 was expressed in E. coli BL21(DE3) (Invitrogen)
transformed with pET-21 containing the Sm29 cDNA sequence and pu-
rified by metal affinity chromatography as previously described (24). To
generate the primary antibody, three BALB/c mice were immunized sub-
cutaneously with three doses of rSm29 (25 g) adsorbed to aluminum
hydroxide (250 g) with 2-week intervals between doses. Fifteen days
after the last dose, cardiac puncture of anesthetized mice was performed
for blood collection and serum processing.
Statistical analysis. For statistical analysis, the GraphPad Prism 5 soft-
ware (GraphPad, La Jolla, CA, USA) was used. The relationship between
pJH-egfp and the pJK library in the initial screening was tested by two-
tailed Spearman rank correlation. The fluorescence induced by pJK in M.
smegmatis or BCG was analyzed by one-way analysis of variance
(ANOVA) and Tukey’s posttest. Correlation of interspecies fluorescence
was tested with a nonparametric Spearman test. Growth curves were com-
pared by nonlinear regression.
RESULTS
Generation of the PL5 promoter library. First, we used error-
prone PCR (25) to generate a library of PL5 promoters and assess
the strengths of variant sequences by cloning the promoters to
drive enhanced green fluorescent protein (eGFP) expression (Fig.
1B). The wild-type PL5 promoter and the egfp gene were cloned
into pJH152, generating pJH-egfp (Fig. 1A), which was used to
transform M. smegmatis, thus representing the fluorescence in-
duced by the original promoter, which correlated with bacterial
growth (Fig. 2A). The pJK plasmid library was used to transform
M. smegmatis, and the approximately 200 colonies named pJK-
XA1 to -YH12 were screened by fluorimetry and demonstrated a
wide variation in fluorescence levels, ranging between 103 and 106
FU (Fig. 2B).
Characterization of selected M. smegmatis/pJK strains. On
the basis of the initial screening, five strains covering the fluores-
cence range were selected for further analysis. First, the sequenc-
ing of selected promoters revealed multiple mutations with mod-
ification in 6 to 11% of their sequences (Fig. 3). Since the ODs of
M. smegmatis/pJK library mutants varied between 0.3 and 1.5, the
data were normalized and fluorescence levels were plotted in RFU
(Fig. 4A). Likewise, confocal microscopy confirmed the differen-
tial expression of GFP where the fluorescence was distributed
throughout the bacillus cell (Fig. 4B). To exclude the possibility
that differential fluorescence would be a consequence of impaired
growth or a distinct rate of GFP expression, selectedM. smegmatis/
pJK strains were evaluated for single-cell fluorescence during
growth. Constant fluorescence was observed during the growth of
each mutant strain (not shown). M. smegmatis/pJK-C1 was the
only strain whose growth was demonstrated to be significantly
different from that of the wild-type strain (see Fig. S1 in the sup-
plemental material).
Flow cytometry of M. smegmatis and M. bovis BCG/pJK
strains. The selected pJK plasmids were transformed into M. bovis
BCG, and late-log-phase cultures were analyzed alongside recom-
binantM. smegmatis by flow cytometry. After gating of the bacilli’s
population, fluorescence was determined as the median FITC
value. M. smegmatis transformed with pJK-F8 showed high fluo-
rescence; M. smegmatis transformed with pJK-B7, pJK-E6, and
pJK-D6 showed intermediate fluorescence; and M. smegmatis
transformed with pJK-C1 showed strikingly low fluorescence (Fig.
5A). Recombinant M. smegmatis strains were also submitted to
SDS-PAGE, and the bands corresponding to GFP were quantified
by densitometry (Fig. 5B). The results demonstrated that the flu-
orescence intensity measured by flow cytometry correlated with
Kanno et al.
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the amount of protein produced (r value 0.96) according to the
strength of each promoter. BCG transformed with the same plas-
mids revealed a high correlation with the observed fluorescence of
M. smegmatis (r value 0.94) (not shown), where all of the mu-
tants of both species maintained their high, intermediate, or low
strength. pJHsp60 demonstrated a strength comparable to that of
the lowest-expression vector, pJK-C1 (Fig. 6).
Mutant promoters induce differential antigen expression.
To investigate the usefulness of these promoters for the expression
of other heterologous genes, we replaced the egfp gene from pJK-
F8, pJK-B7, and pJK-C1 with the codon-optimized sm29 gene
from S. mansoni. Since pJK-F8 produced no colonies after trans-
formation, further work was done with pJK-B7 and pJK-C1. rBCG
clones of these strains were grown to late log phase and lysed by
sonication. Total protein extracts were analyzed by Western blot
assay with specific anti-rSm29 antibodies. As predicted, we ob-
tained a more intense immunoblot assay result with the rBCG/
pJK-B7.Sm29 extracts (higher promoter activity) than with the
reaction in the rBCG/pJK-C1.Sm29 extracts (lower promoter ac-
tivity) at the same molecular weight as recombinant protein
rSm29, but no immunoreaction was observed in wild-type BCG
protein extracts (Fig. 7).
DISCUSSION
Here we used the gene for eGFP as a reporter to measure the
differential expression of this protein induced by mutations in the
regulatory region of the mycobacteriophage L5 PL5 promoter se-
quence. The PL5 promoter regulatory sequence was subjected to
random mutagenesis, and a library of promoters exhibiting differ-
ent strengths, as measured by fluorescence, was selected. The gene
for GFP is one of the reporters most often used to characterize
promoter strength among many organisms in a quantitative fash-
FIG 2 Screening of PL5 promoter mutant strength. (A) Clones of M. smegmatis/pJH-egfp with the nonmutated PL5 promoter show a correlation between growth
(OD620) and fluorescence (log10 FU) (r 0.79). (B) M. smegmatis transformed with a pJK plasmid library shows a variation in fluorescence independently of
growth (r 0.26). Wild-type M. smegmatis (no egfp gene) and M. smegmatis/pJH-egfp are represented by a black triangle and a star, respectively. The mutants
selected for further analysis are represented by black circles. Statistical analysis was done by two-tailed Spearman rank correlation.
FIG 3 Sequence alignment of wild-type and mutated PL5 promoters in pJK plasmids. The promoter sequence containing the selected pJK plasmids was
sequenced and compared to the original. Of 257 bp comprising the promoter region, 6 to 11% are altered in mutants; they also localized to the predicted10 and
35 regions. pJK-C1 showed a mutation at the transcriptional starting site (TSS). The initiation codon is the last 3 bp in the sequence shown.
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ion (26–28), including in mycobacterial species for promoter dis-
covery, strength, and trafficking in the host (11, 29–32).
The observed 6 to 11% mutations in the regulatory sequence is
consistent with the expected rate of 10 to 15% mutagenesis with
equimolar concentrations of altered and natural dNTPs (25). A
higher degree of mutation can span a wider range of downstream
expression; however, it can also abolish expression by altering
motifs important for transcriptional factor binding. During in
vitro growth, the M. smegmatis/pJK mutants selected showed a
stable level of fluorescence. The PHsp60 promoter placed in the
same plasmid backbone as the pJK series induced a fluorescence
intensity comparable to that obtained with the weakest PL5 pro-
moter, thus indicating the high strength of PL5. Heat shock treat-
ment did not increase the fluorescence of M. smegmatis/pJK or
pJHsp60 (not shown). It could be argued that fluorescence may
not serve as a good parameter to determine protein expression and
ultimately promoter activity. However, here we have demon-
strated that fluorescence determined by flow cytometry correlates
with the total amount of GFP expression in SDS-PAGE even
though only six promoters were used.
In this study, we observed mutations throughout the whole
sequence, including the 10 and 35 regions of the promoters,
exhibiting high, medium, or low strength. Interestingly, all of the
midstrength promoters (pJK-B7, pJK-E6, and pJK-D6) showed a
mutation at the first position of the10 region (C¡T). Also, the
weakest promoter that we identified, in pJK-C1, is the only one
with a mutation at the predicted transcriptional start site (A¡G).
Heterologous expression in recombinant bacteria can be dele-
terious or lethal. Given the relatively low mycobacterial growth
rate, where faster-growing strains like M. smegmatis and M. for-
tuitum have a doubling time of 2 to 3 h and M. bovis BCG and M.
tuberculosishave a doubling time of 20 to 24 h (33), eGFP synthesis
undoubtedly represents a metabolic burden and stress through
consumption of ATP, nucleotides, and amino acids and usage of
ribosomes and tRNAs that may displace the expression of endog-
enous proteins and hence inhibit the bacillus’s growth. GFP itself
FIG 4 Error-prone PCR changes PL5 promoter strength. (A) Relative fluorescence (RFU) of selected transformants comprising the fluorescence range. (B)
Microscopy of M. smegmatis/pJK demonstrating differential fluorescence with respect to promoter strength, with little variation among the bacillus population.
Statistical analysis was done by one-way ANOVA (***, P 0.001; ns, not significant).
FIG 5 pJK plasmids induce differential expression in M. smegmatis. Late-log-phase cultures of M. smegmatis were transformed with selected pJK plasmids or
pJHsp60. (A) Fluorescence of recombinant M. smegmatis harboring pJK plasmids analyzed by flow cytometry. (B) Relative density of the GFP band on
SDS-PAGE analyzed by densitometry. Statistical analysis was done by one-way ANOVA (***, P 0.001; **, P 0.01; ns, not significant).
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can also be toxic to the host (26). Nevertheless, in this study, the
only strain significantly different from the wild type in growth was
M. smegmatis/pJK-C1. This strain appears to have a lag at early
time points but reaches a similar OD at later time points. How-
ever, it is unlikely that low and not high eGFP expression could
inhibit growth, as observed by others (34).
To evaluate the utility of PL5 promoters for driving foreign
antigen expression in BCG, the sm29 gene from S. mansoni was
cloned in place of the egfp gene downstream of a strong (pJK-F8),
an intermediate (pJK-B7), or a weak (pJK-C1) mutant promoter.
rBCG expressed Sm29 at different levels, which corresponded to
their eGFP-measured promoter strength. pJK-F8 was not evalu-
ated since no colonies of rBCG were obtained, even after several
attempts.
rBCG/pJK-B7 clones were 9-fold more fluorescent than rBCG/
pJK-C1 clones (average FITC values of 27,300 and 3,200, respec-
tively). To achieve such a difference, Bourn et al. used an enrich-
ment method to select for high-copy-number variants of plasmid
pORI101 with GFP expression 7-fold higher than that of the orig-
inal (16). Although this strategy can be useful in obtaining signif-
icant expression of cloned genes, some disadvantages, such as a
metabolic burden and plasmid instability, may reduce the useful-
ness of the system.
Since pJK plasmids are extrachromosomal, their copy number
could be partially responsible for the differences in fluorescence or
Sm29 expression observed among mycobacterial hosts. The origin
of replication of pJH-egfp and pJK is derived from pAL5000 of M.
fortuitum, which is widely used in mycobacterial shuttle plasmids
such as pMV261, pLA71, and pMIP12. Its copy number in M.
smegmatis was determined as 3 by Southern blot assay (35), 8 by
antibiotic resistance (36), and 23 by quantitative PCR (37). The
variation of the copy number among these studies can be ex-
plained by the different methods of quantification used but also by
the differences in plasmid structure. Despite the same pAL5000-
derived origin of replication, other features such as the resistance
marker, size, and some other elements are also different. In our
study, all of the features are the same, with the exception of a few
nucleotides at the promoter sequence. Thus, we expect to mini-
mize the effect of the plasmid copy number on differential expres-
sion. Besides that, although there are minor variations in fluores-
cence during the growth of recombinant M. smegmatis, the
fluorescence values do not intersect each other.
In conclusion, this study demonstrates the utility of the ratio-
nal design of systems to obtain a range of expression of target
proteins in mycobacteria. The systems described present an alter-
native way to obtain the expression of foreign genes in mycobac-
teria and to design a new generation of rBCG vaccines that opti-
mize the host immune response for protection.
ACKNOWLEDGMENTS
This work was supported by FAPESP grant 2008/04631-7, by San-
tander through its program Santander Universities and Fundação Bu-
tantan, and by BBSRC grant BB/J002097/1.
We thank S. T. Cole for the generous gift of pJH152 and G. F. Hatfull
for pBRL8.
FUNDING INFORMATION
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) pro-
vided funding to Alex Issamu Kanno under grant number 2008/04631-7.
The funders had no role in study design, data collection and interpreta-
tion, or the decision to submit the work for publication.
REFERENCES
1. Bloom BR, Snapper SB, Kieser T, Jacobs WR. 1990. Development of
recombinant BCG vaccines. Semin Virol 1:7.
2. Bastos RG, Borsuk S, Seixas FK, Dellagostin OA. 2009. Recombinant
Mycobacterium bovis BCG. Vaccine 27:6495– 6503. http://dx.doi.org/10
.1016/j.vaccine.2009.08.044.
3. Fuerst TR, de la Cruz VF, Bansal GP, Stover CK. 1992. Development
and analysis of recombinant BCG vector systems. AIDS Res Hum Retro-
viruses 8:1451–1455.
4. Ohara N, Yamada T. 2001. Recombinant BCG vaccines. Vaccine 19:
4089 – 4098. http://dx.doi.org/10.1016/S0264-410X(01)00155-4.
5. Dale JW, Dellagostin OA, Norman E, Barret ADT, McFadden J. 1993.
Multivalent BCG vaccines, p 87–109. In O’Hagan DT (ed), Novel delivery
systems for oral vaccines. CRC Press, Boca Raton, FL.
6. Dhar N, Rao V, Tyagi AK. 2004. Immunogenicity of recombinant BCG
vaccine strains overexpressing components of the antigen 85 complex of
Mycobacterium tuberculosis. Med Microbiol Immunol 193:19 –25. http:
//dx.doi.org/10.1007/s00430-002-0170-x.
7. Dhar N, Rao V, Tyagi AK. 2003. Skewing of the Th1/Th2 responses in
mice due to variation in the level of expression of an antigen in a recom-
binant BCG system. Immunol Lett 88:175–184. http://dx.doi.org/10.1016
/S0165-2478(03)00043-9.
8. Galen JE, Levine MM. 2001. Can a ‘flawless’ live vector vaccine strain be
engineered? Trends Microbiol 9:372–376. http://dx.doi.org/10.1016
/S0966-842X(01)02096-0.
9. Edelman R, Palmer K, Russ KG, Secrest HP, Becker JA, Bodison SA,
Perry JG, Sills AR, Barbour AG, Luke CJ, Hanson MS, Stover CK,
Burlein JE, Bansal GP, Connor EM, Koenig S. 1999. Safety and immu-
nogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing
Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult
FIG 6 pJK plasmids induce differential fluorescence levels in M. bovis BCG.
Late-log-phase cultures of BCG were transformed with pJK plasmids or
pJHsp60, and fluorescence was analyzed by flow cytometry. Statistical analysis
was done by one-way ANOVA (***, P 0.001; ns, not significant).
FIG 7 Western blot assay of rBCG strains differentially expressing Sm29 an-
tigen through mutated PL5 promoters. Total protein extracts (25 g) of wild-
type BCG (lane 2), rBCG/pJK-C1.Sm29 (lanes 3), and pJK-B7.Sm29 (lanes 4)
were used. Two independently isolated clones were analyzed by Western blot
assay with anti-rSm29 antibodies. A 300-ng sample of rSm29 protein (lane 1)
was used as a positive control. The values to the left are molecular sizes in
kilodaltons.
New Recombinant BCG Expression Vectors
April 2016 Volume 82 Number 8 aem.asm.org 2245Applied and Environmental Microbiology
 o
n
 April 18, 2016 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
volunteers: a candidate Lyme disease vaccine. Vaccine 17:904 –914. http:
//dx.doi.org/10.1016/S0264-410X(98)00276-X.
10. Varaldo PB, Leite LC, Dias WO, Miyaji EN, Torres FI, Gebara VC,
Armoa GR, Campos AS, Matos DC, Winter N, Gicquel B, Vilar MM,
McFadden J, Almeida MS, Tendler M, McIntosh D. 2004. Recombinant
Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma
mansoni protects mice from cercarial challenge. Infect Immun 72:3336 –
3343. http://dx.doi.org/10.1128/IAI.72.6.3336-3343.2004.
11. Ehrt S, Guo XV, Hickey CM, Ryou M, Monteleone M, Riley LW,
Schnappinger D. 2005. Controlling gene expression in mycobacteria with
anhydrotetracycline and Tet repressor. Nucleic Acids Res 33:e21. http://dx
.doi.org/10.1093/nar/gni013.
12. Kanekiyo M, Matsuo K, Hamatake M, Hamano T, Ohsu T, Matsumoto
S, Yamada T, Yamazaki S, Hasegawa A, Yamamoto N, Honda M. 2005.
Mycobacterial codon optimization enhances antigen expression and vi-
rus-specific immune responses in recombinant Mycobacterium bovis
bacille Calmette-Guérin expressing human immunodeficiency virus type
1 Gag. J Virol 79:8716 – 8723. http://dx.doi.org/10.1128/JVI.79.14.8716
-8723.2005.
13. Varaldo PB, Miyaji EN, Vilar MM, Campos AS, Dias WO, Armoa GR,
Tendler M, Leite LC, McIntosh D. 2006. Mycobacterial codon optimi-
zation of the gene encoding the Sm14 antigen of Schistosoma mansoni in
recombinant Mycobacterium bovis bacille Calmette-Guérin enhances pro-
tein expression but not protection against cercarial challenge in mice.
FEMS Immunol Med Microbiol 48:132–139. http://dx.doi.org/10.1111/j
.1574-695X.2006.00133.x.
14. Fan XY, Ma H, Guo J, Li ZM, Cheng ZH, Guo SQ, Zhao GP. 2009. A
novel differential expression system for gene modulation in mycobacteria.
Plasmid 61:39 – 46. http://dx.doi.org/10.1016/j.plasmid.2008.09.002.
15. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J,
Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S. 2010.
Optimisation of bioluminescent reporters for use with mycobacteria.
PLoS One 5:e10777. http://dx.doi.org/10.1371/journal.pone.0010777.
16. Bourn WR, Jansen Y, Stutz H, Warren RM, Williamson AL, van Helden
PD. 2007. Creation and characterisation of a high-copy-number version
of the pAL5000 mycobacterial replicon. Tuberculosis (Edinb) 87:481–
488. http://dx.doi.org/10.1016/j.tube.2007.08.003.
17. Hatfull GF, Sarkis GJ. 1993. DNA sequence, structure and gene expres-
sion of mycobacteriophage L5: a phage system for mycobacterial genetics.
Mol Microbiol 7:395– 405. http://dx.doi.org/10.1111/j.1365-2958.1993
.tb01131.x.
18. Nesbit CE, Levin ME, Donnelly-Wu MK, Hatfull GF. 1995. Tran-
scriptional regulation of repressor synthesis in mycobacteriophage L5.
Mol Microbiol 17:1045–1056. http://dx.doi.org/10.1111/j.1365-2958
.1995.mmi_17061045.x.
19. Taylor RG, Walker DC, Mcinnes RR. 1993. Escherichia coli host strains
significantly affect the quality of small-scale plasmid DNA preparations
used for sequencing. Nucleic Acids Res 21:1677–1678. http://dx.doi.org
/10.1093/nar/21.7.1677.
20. Snapper SB, Melton RE, Mustafa S, Kieser T, Jacobs WR, Jr. 1990.
Isolation and characterization of efficient plasmid transformation mu-
tants of Mycobacterium smegmatis. Mol Microbiol 4:1911–1919. http://dx
.doi.org/10.1111/j.1365-2958.1990.tb02040.x.
21. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, Dos
Santos S, Duthoy S, Lacroix C, Garcia-Pelayo C, Inwald JK, Golby P,
Garcia JN, Hewinson RG, Behr MA, Quail MA, Churcher C, Barrell BG,
Parkhill J, Cole ST. 2007. Genome plasticity of BCG and impact on
vaccine efficacy. Proc Natl Acad Sci U S A 104:5596 –5601. http://dx.doi
.org/10.1073/pnas.0700869104.
22. Parish T, Stoker NG. 1998. Electroporation of mycobacteria. Methods
Mol Biol 101:129 –144.
23. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, deMelo AL, Caliari
MV, Almeida GT, Venancio TM, Verjovski-Almeida S, Oliveira SC. 2008.
Schistosoma mansoni tegument protein Sm29 is able to induce a Th1 type
of immune response and protection against parasite infection. PLoS Negl
Trop Dis 2:e308. http://dx.doi.org/10.1371/journal.pntd.0000308.
24. Cardoso FC, Pacifico RN, Mortara RA, Oliveira SC. 2006. Human
antibody responses of patients living in endemic areas for schistosomiasis
to the tegumental protein Sm29 identified through genomic studies. Clin
Exp Immunol 144:382–391. http://dx.doi.org/10.1111/j.1365-2249.2006
.03081.x.
25. Zaccolo M, Williams DM, Brown DM, Gherardi E. 1996. An approach
to random mutagenesis of DNA using mixtures of triphosphate deriva-
tives of nucleoside analogues. J Mol Biol 255:589 – 603. http://dx.doi.org
/10.1006/jmbi.1996.0049.
26. Alper H, Fischer C, Nevoigt E, Stephanopoulos G. 2005. Tuning genetic
control through promoter engineering. Proc Natl Acad Sci U S A 102:
12678 –12683. http://dx.doi.org/10.1073/pnas.0504604102.
27. Davis JH, Rubin AJ, Sauer RT. 2011. Design, construction and charac-
terization of a set of insulated bacterial promoters. Nucleic Acids Res
39:1131–1141. http://dx.doi.org/10.1093/nar/gkq810.
28. Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, Lahn BT. 2010.
Systematic comparison of constitutive promoters and the doxycycline-
inducible promoter. PLoS One 5:e10611. http://dx.doi.org/10.1371
/journal.pone.0010611.
29. Gall K, Barker LP. 2006. Differential green fluorescent protein expression
from mycobacterial promoter constructs in Escherichia coli and Mycobac-
teriummarinum. FEMS Microbiol Lett 255:301–307. http://dx.doi.org/10
.1111/j.1574-6968.2005.00078.x.
30. Kremer L, Baulard A, Estaquier J, Poulain-Godefroy O, Locht C. 1995.
Green fluorescent protein as a new expression marker in mycobacteria.
Mol Microbiol 17:913–922. http://dx.doi.org/10.1111/j.1365-2958.1995
.mmi_17050913.x.
31. Müller-Taubenberger A, Anderson KI. 2007. Recent advances using
green and red fluorescent protein variants. Appl Microbiol Biotechnol
77:1–12. http://dx.doi.org/10.1007/s00253-007-1131-5.
32. Triccas JA, Britton WJ, Gicquel B. 2001. Isolation of strong expression
signals of Mycobacterium tuberculosis. Microbiology 147:1253–1258.
http://dx.doi.org/10.1099/00221287-147-5-1253.
33. Dziadek J, Madiraju MV, Rutherford SA, Atkinson MA, Rajagopalan
M. 2002. Physiological consequences associated with overproduction of
Mycobacterium tuberculosis FtsZ in mycobacterial hosts. Microbiology
148:961–971. http://dx.doi.org/10.1099/00221287-148-4-961.
34. Luo Y, Szilvasi A, Chen X, DeWolf WC, O’Donnell MA. 1996. A novel
method for monitoring Mycobacterium bovis BCG trafficking with recom-
binant BCG expressing green fluorescent protein. Clin Diagn Lab Immu-
nol 3:761–768.
35. Ranes MG, Rauzier J, Lagranderie M, Gheorghiu M, Gicquel B. 1990.
Functional analysis of pAL5000, a plasmid fromMycobacterium fortuitum:
construction of a “mini” mycobacterium-Escherichia coli shuttle vector. J
Bacteriol 172:2793–2797.
36. Gavigan JA, Ainsa JA, Perez E, Otal I, Martin C. 1997. Isolation by
genetic labeling of a new mycobacterial plasmid, pJAZ38, from Mycobac-
terium fortuitum. J Bacteriol 179:4115– 4122.
37. Huff J, Czyz A, Landick R, Niederweis M. 2010. Taking phage integra-
tion to the next level as a genetic tool for mycobacteria. Gene 468:8 –19.
http://dx.doi.org/10.1016/j.gene.2010.07.012.
Kanno et al.
2246 aem.asm.org April 2016 Volume 82 Number 8Applied and Environmental Microbiology
 o
n
 April 18, 2016 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
